Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Buthiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buthiazide SCHEMBL309110 | 0.89 | TDP1 (0.76) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| Buthiazide SCHEMBL29364486 | 0.89 | TDP1 (0.76) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| Chlorothiazide SCHEMBL26200 | 0.80 | CA1 (0.51) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| Chlorothiazide SCHEMBL30594143 | 0.80 | CA1 (0.51) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| Chlorothiazide SCHEMBL3966861 | 0.80 | CA1 (0.51) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| Chlorothiazide SCHEMBL119091 | 0.79 | CA1 (0.50) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| Chlorothiazide SCHEMBL29040938 | 0.79 | CA1 (0.50) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| Chlorothiazide SCHEMBL29227709 | 0.79 | CA1 (0.50) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| Chlorothiazide SCHEMBL28312721 | 0.79 | CA1 (0.50) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL13685945 | 0.78 | TDP1 (0.79) | TDP1LMNAALDH1A1CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0883403-A4 | METHOD FOR TREATING SEXUAL DYSFUNCTIONS | UNIV CALIFORNIA (US) | 2002-03-06 | — | — | EP | disclosed |
| EP-1026950-A1 | TREATMENT OF SCHIZOPHRENIA WITH AMPAKINES AND NEUROLEPTICS | CORTEX PHARMACEUTICALS, INC. (US) | 2000-08-16 | — | — | EP | disclosed |
| EP-0850058-A4 | FACILITATION OF AMPA RECEPTOR-MEDIATED SYNAPTIC TRANSMISSION IN BRAIN AS A TREATMENT FOR SCHIZOPHRENIA | UNIV CALIFORNIA (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999021422-A1 | TREATMENT OF SCHIZOPHRENIA WITH AMPAKINES AND NEUROLEPTICS | CORTEX PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| EP-0883403-A1 | METHOD FOR TREATING SEXUAL DYSFUNCTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-12-16 | — | — | EP | disclosed |
| EP-0850058-A1 | FACILITATION OF AMPA RECEPTOR-MEDIATED SYNAPTIC TRANSMISSION IN BRAIN AS A TREATMENT FOR SCHIZOPHRENIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997026884-A1 | METHOD FOR TREATING SEXUAL DYSFUNCTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997007799-A1 | FACILITATION OF AMPA RECEPTOR-MEDIATED SYNAPTIC TRANSMISSION IN BRAIN AS A TREATMENT FOR SCHIZOPHRENIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-03-06 | — | — | WO | disclosed |